| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8958409 | Journal of Thoracic Oncology | 2018 | 10 Pages |
Abstract
ROS1-positive NSCLC has distinct clinical characteristics, with an effective and durable response to both TKIs and pemetrexed-based chemotherapies. Regardless, given its novel characteristics and distinct clinical responses to conventional chemotherapies and TKIs, the treatment strategy for ROS1-positive NSCLC remains to be further developed.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Sehhoon MD, Beung-Chul MD, Sung Won MD, Jong-Mu MD, PhD, Hye Ryun MD, PhD, Min Hee MD, Se-Hoon MD, PhD, Jin Seok MD, PhD, Keunchil MD, PhD, Yoon La MD, PhD, Byoung Chul MD, PhD, Myung-Ju MD, PhD,